Melanie Royce
AuthID: R-00G-SRK
1
TÃTULO: Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
AUTORES: Melanie Royce; Thomas Bachelot; Cristian Villanueva; Mustafa Ozguroglu; Sergio J Azevedo; Felipe Melo Cruz; Marc Debled; Roberto Hegg; Tatsuya Toyama; Carla Falkson; Joon Jeong; Vichien Srimuninnimit; William J Gradishar; Christina Arce; Antonia Ridolfi; Chinjune J Lin; Fatima Cardoso;
PUBLICAÇÃO: 2018, FONTE: JAMA ONCOLOGY, VOLUME: 4, NÚMERO: 7
AUTORES: Melanie Royce; Thomas Bachelot; Cristian Villanueva; Mustafa Ozguroglu; Sergio J Azevedo; Felipe Melo Cruz; Marc Debled; Roberto Hegg; Tatsuya Toyama; Carla Falkson; Joon Jeong; Vichien Srimuninnimit; William J Gradishar; Christina Arce; Antonia Ridolfi; Chinjune J Lin; Fatima Cardoso;
PUBLICAÇÃO: 2018, FONTE: JAMA ONCOLOGY, VOLUME: 4, NÚMERO: 7
INDEXADO EM: 
Scopus 
WOS
Scopus WOS2
TÃTULO: Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
AUTORES: Bachelot, T; Royce, M; Villanueva, C; Melo Cruz, FM; Hegg, R; Falkson, C; Jeong, J; Srimuninnimit, V; Arce, CH; Ridolfi, A; Lin, C; Gradishar, W; Ozguroglu, M; Cardoso, F; Azevedo, S;
PUBLICAÇÃO: 2017, FONTE: 42nd European-Society-for-Medical-Oncology Congress (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 28
AUTORES: Bachelot, T; Royce, M; Villanueva, C; Melo Cruz, FM; Hegg, R; Falkson, C; Jeong, J; Srimuninnimit, V; Arce, CH; Ridolfi, A; Lin, C; Gradishar, W; Ozguroglu, M; Cardoso, F; Azevedo, S;
PUBLICAÇÃO: 2017, FONTE: 42nd European-Society-for-Medical-Oncology Congress (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 28
INDEXADO EM: WOS
WOS3
TÃTULO: BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
AUTORES: Royce, M; Villanueva, C; Ozguroglu, M; Bachelot, T; Azevedo, S; Melo Cruz, FM; Hegg, R; Debled, M; Gradishar, WJ; Manlius, C; Ridolfi, A; Lin, J; Ringeisen, F; Cardoso, F;
PUBLICAÇÃO: 2016, FONTE: ANNALS OF ONCOLOGY, VOLUME: 27
AUTORES: Royce, M; Villanueva, C; Ozguroglu, M; Bachelot, T; Azevedo, S; Melo Cruz, FM; Hegg, R; Debled, M; Gradishar, WJ; Manlius, C; Ridolfi, A; Lin, J; Ringeisen, F; Cardoso, F;
PUBLICAÇÃO: 2016, FONTE: ANNALS OF ONCOLOGY, VOLUME: 27
INDEXADO EM: WOS
WOS4
TÃTULO: BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) Full Text
AUTORES: Thomas Bachelot; Cristian Villanueva; Melanie Royce; Marc Debled; Felipe Melo Cruz; Roberto Hegg; Thomas Brechenmacher; Corinne Manlius; Francois Ringeisen; Fatima Cardoso;
PUBLICAÇÃO: 2015, FONTE: BREAST, VOLUME: 24
AUTORES: Thomas Bachelot; Cristian Villanueva; Melanie Royce; Marc Debled; Felipe Melo Cruz; Roberto Hegg; Thomas Brechenmacher; Corinne Manlius; Francois Ringeisen; Fatima Cardoso;
PUBLICAÇÃO: 2015, FONTE: BREAST, VOLUME: 24
INDEXADO EM: WOS
WOS